Drug Profile
Tolinapant - Astex Pharmaceuticals
Alternative Names: ASTX 660Latest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Astex Therapeutics
- Developer Astex Pharmaceuticals; Emory University; Otsuka Pharmaceutical
- Class Antineoplastics; Fluorinated hydrocarbons; Ketones; Morpholines; Piperazines; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Inhibitor of apoptosis protein inhibitors; X-linked inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lymphoma; Solid tumours
- Phase I/II Peripheral T-cell lymphoma; T-cell lymphoma
- Phase I Colorectal cancer; Squamous cell cancer
- Preclinical Precursor T-cell lymphoblastic leukaemia-lymphoma
- No development reported Acute myeloid leukaemia
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from phase I/II clinical trials in Peripheral T-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 08 Nov 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA prior to November 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)
- 08 Nov 2023 Discontinued - Phase-II for Lymphoma in USA prior to November 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)